Overview
To study the safety and clinical effect of injection of drug-eluting microspheres with multiple chemodrug and protein drugs into advanced solid tumors.
Description
Drug-eluting microspheres such as DC-beads will be loaded with IL2, PD1/PDL1/CTLA4 antibody, or /and VEGF/VEGFR antibody with or without doxorubicin/idarubicin for various time and injected into tumors under CT guidance. Side effects and treatment efficacy after injection of drug-eluting microspheres into malignant tumors will be assessed according to RICEST1.1 standard.
Eligibility
Inclusion Criteria:
- Solid advanced malignant tumors
- Age between18 and 99 years
- Life expectancy is greater than three months
Exclusion Criteria:
- Benign tumor
- Life expectancy is less than three months
- Serious medical comorbidity
- Others